Announcement
Thank you for attending THSNA 2026. The virtual meeting is now closed.
Thank you for attending THSNA 2026. The virtual meeting is now closed.
Presentation Details
| Evaluation of Compliance with Recommendation to Take Rivaroxaban with Food Nghi Ha, Erin Mouland, Denise Sutter-Long, Elizabeth Renner, Anisa Bici. Michigan Medicine, Ann Arbor, MI, USA |
Abstract
Purpose: Rivaroxaban is a common anticoagulant used for the prevention of stroke in patients with atrial fibrillation (Afib) and in the prevention and treatment of thrombosis in patients with venous thromboembolism (VTE). Current recommendation requires that patients on rivaroxaban 15 mg or 20 mg daily take it with food, as food affects its absorption. Bioavailability for rivaroxaban 20 mg is estimated at 66% in a fasted state vs. high bioavailability (> 80%) with food. Suboptimal dosing from decreased bioavailability may result in negative clinical outcomes. This study aims to assess the proportion of patients on rivaroxaban who are noncompliant with taking it with food and to identify potential predictors between patients taking rivaroxaban with food and without food. Method: A retrospective cohort study assessing patients taking rivaroxaban with food versus without food. Patients were included if they were taking rivaroxaban 15 mg daily or 20 mg daily, for the indication of Afib or VTE, referred to an anticoagulation service for perioperative management between 8/2023-8/2024. Rivaroxaban administration was assessed as part of the perioperative management process. Result: A total of 313 patients were included in the analysis. Of those, 43 (14%) patients were not taking rivaroxaban with food. Both cohorts (rivaroxaban with food vs. without food) had similar age (66 vs. 65 years old, p = 0.70) and proportion of male sex (58% vs. 60%, p = 0.78). The majority of patients in both cohorts were taking rivaroxaban for Afib, (62% vs. 63%, p = 0.94) with similar mean CHAD2-VASc score (3.2 vs. 2.7, p = 0.07). Majority of patients in both cohorts were identified as White/Caucasian (80% vs. 88%, p = 0.44). Similar proportion of patients were referred to the anticoagulation service by a cardiologist/electrophysiologist (52% vs. 47%, p = 0.72). Both cohorts had similar number of concomitant medications (13 vs. 14, p = 0.36). There were no significant predictors for noncompliance on univariate or multivariate analysis after accounting for age, male sex, indication, white ethnicity, or referral by a cardiologist/electrophysiologist. Conclusion: Approximately 14% of patients on rivaroxaban are not taking it with food, as recommended. Suboptimal absorption may result in suboptimal outcomes. All patients on rivaroxaban (15 mg or 20 mg dosage) should be assessed for compliance with taking rivaroxaban with food and may benefit from reinforcement in the form of patient education.
No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author.
No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author.